Charts

News

17 Jun, 2024
Petros Pharmaceuticals Inc (NASDAQ:PTPI) is a pharmaceutical company focusing on men’s health therapeutics. In an interview ...
13 Jun, 2024
Shares of Signet Jewelers Limited (NYSE:SIG) fell sharply during Thursday's session following mixed first-quarter earnings including an ...
Gainers Longeveron (NASDAQ:LGVN) stock increased by 74.6% to $3.16 during Thursday's regular session. The company's market cap stands ...
Shares of Broadcom Inc. (NASDAQ:AVGO) rose sharply in today's pre-market trading after the company posted stronger-than-expected results ...
Gainers Longeveron (NASDAQ:LGVN) stock rose 30.9% to $2.37 during Thursday's pre-market session. The company's market cap stands at ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are worth checking out on Thursday as we break down all of the hottest stock market news this morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future”
29 May, 2024
Gainers OneMedNet (NASDAQ:ONMD) shares increased by 52.3% to $2.97 during Wednesday's after-market session. The company's market cap ...
Study paves the way toward a first-ever innovation program to include AI-optimization for FDA-guided Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused ...
Study paves the way toward a first-ever innovation program to include AI-optimization for FDA-guided Rx-to-OTC switch
21 May, 2024
Team composed of former FDA officials and key clinical and regulatory opinion leaders to help provide insight in preparation for collaboration with FDA
16 May, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips PTPI stock results show that Petros Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. The post PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
14 May, 2024
Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activitySUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Petros Pharmaceuticals, Inc.’s (Nasdaq: PTPI), prescription erectile dysfunction (ED) medication STENDRAⓇ (avanafil) through its telehealth platform. Working direct
Lemonaid Health will offer customers more affordable access to branded ED medication STENDRA that may be taken as early as ~15 minutes prior to sexual activity (100mg and 200mg strengths only) [1]
23 Apr, 2024
Collaboration with leading telemedicine provider to offer marketing and distribution of STENDRA for Lemonaid Health's ED patients(Please see important safety information below)
16 Apr, 2024
(Please see important safety information below) NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Petros Pharmaceuticals, Inc. ("Petros," or the "Company") (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter ...
02 Apr, 2024
Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips PTPI stock results show that Petros Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. The post PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
Gainers MSP Recovery (NASDAQ:LIFW) stock increased by 61.9% to $1.08 during Tuesday's pre-market session. The company's market cap ...
Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56% of all users) underscoring the significant potential benefits of technology assistance in an OTC setting
19 Mar, 2024
Petros begins enrollment in AI integrated Human Factors Study to optimize self-screening, continuing its efforts to make STENDRA (avanafil) the first erectile dysfunction medication to achieve OTC Status
14 Feb, 2024
AI software expected to further enable Petros's efforts to make STENDRA the first ED product to be offered over the counter
30 Jan, 2024
Gainers SINTX Techs (NASDAQ:SINT) shares increased by 75.0% to $0.41 during Tuesday's after-market session. The market value of their ...
Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported ...
Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) shares rose sharply in today’s pre-market trading as the company posted ...
25 Jan, 2024
Gainers Inspire Veterinary (NASDAQ:IVP) stock moved upwards by 37.5% to $0.26 during Thursday's after-market session. The market value ...
24 Jan, 2024
FDA requests meeting to review the Company's technology component and discuss further development and requirements
17 Jan, 2024
Over 78% of technology-enabled subjects correctly self-selected vs. 56% using drug facts label alone demonstrating continued progress toward STENDRA® working to become the first erectile dysfunction medication to successfully achieve OTC status NEW ...
Over 78% of technology-enabled subjects correctly self-selected vs. 56% using drug facts label alone demonstrating continued progress toward STENDRA® working to become the first erectile dysfunction medication to successfully achieve OTC status
13 Dec, 2023
Shares of ReShape Lifesciences Inc. (NASDAQ: RSLS) rose sharply in pre-market trading after the company said it received FDA PMA ...
12 Dec, 2023
Human Factor Study represents important component of FDA requirements for technology to pave way for STENDRA OTC approval
Idea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch Approval
05 Dec, 2023
Idea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch Approval
30 Oct, 2023
New AI/machine learning tool designed to help potential users more effectively self-select in the effort to make STENDRA the first erectile dysfunction (ED) medication available OTC
19 Oct, 2023
Important step towards STENDRA potentially becoming the first erectile dysfunction medication to successfully achieve OTC Status
13 Oct, 2023
Gainers Bio-Path Hldgs (NASDAQ:BPTH) stock rose 132.2% to $0.92 during Friday's pre-market session. The company's market cap stands at ...
04 Oct, 2023
Company well positioned to continue collaboration with FDA toward pursuit of OTC pathway for STENDRA
Gainers Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) shares rose 72.4% to $0.2930 in pre-market trading after falling 15% on ...
28 Sep, 2023
NEW YORK, NY / ACCESSWIRE / September 28, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the LD Micro Main Event XVI. The conference is being held on October 3 - 5, 2023 at the Luxe Sunset Boulevard Hotel in Los Angeles.
11 Sep, 2023
Gainers NovaBay Pharmaceuticals (AMEX:NBY) stock rose 109.7% to $1.3 during Monday's pre-market session. The company's market cap ...
NEW YORK, NY / ACCESSWIRE / September 11, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway provides the below Letter to Shareholders:
06 Sep, 2023
NEW YORK, NY / ACCESSWIRE / September 6, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference. The conference is being held on September 11 - 13, 2023 at the Lotte New York Palace Hotel.
17 Jul, 2023
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) shares increased by 89.5% to $0.5 during Monday's after-market session. At the close, ...
14 Jul, 2023
Investors are on the hunt for undervalued, under followed and emerging stocks, and retail traders have countless methods at their ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to start the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live Wall Street Titan: Here’s My #1 Stock for 2023 The $1 Investment You MUST Take Advantage of Right Now It doesn’t matter if you have $500 or $5 million. Do this now.
15 Nov, 2022
30 Nov, 2021
15 Nov, 2021
17 Aug, 2021
17 May, 2021

Related Articles